COVID-19 Can Start With Neurological Symptoms

Modesto Morganelli
Giugno 16, 2020

The trial included thousands of patients, 2,104 of whom were randomly assigned to receive 6 milligrams of dexamethasone per day for ten days, according to Stat News. Both results were statistically significant.

The British government announced on Tuesday that dexamethasone is to be used on COVID-19 patients "from this afternoon".

Patients given dexamethasone and who were not on a ventilator saw death rates drop by a fifth in comparison to standard care.

"We're working with the NHS so that the NHS standard treatment for COVID-19 will include dexamethasone from this afternoon", he added.

"These preliminary results from the RECOVERY trial are very clear - dexamethasone reduces the risk of death among patients with severe respiratory complications".

"This is a (trial) result that shows that if patients who have COVID-19 and are on ventilators or are on oxygen are given dexamethasone, it will save lives, and it will do so at a remarkably low cost", said Martin Landray, an Oxford University professor co-leading the trial, known as the RECOVERY trial. Remdesivir shortens the course of infection, but has not been shown to save lives. When such an attack reaches the lungs, it can trigger acute respiratory distress syndrome, or ARDS, which causes fluid to build up in the air sacs of the lungs, Stat News reported. The researchers found that it is effective on patients whose immune system has gone into overdrive in response to the coronavirus infection. The generic steroid is used to treat a wide variety of conditions, from psoriasis to rheumatoid arthritis, asthma and some cancers, including leukemia, according to the National Cancer Institute.

The Recovery trial also studied the anti-malaria drug hydroxychloroquine, but discontinued its use "due to lack of efficacy". In guidelines for physicians treating the disease, the NIH doesn't even mention the therapy.

Dexamethasone is a cheap and widely-available steroid drug that has become the first medicine shown to be able to save lives of patients severely affected by COVID-19.

The result, should it hold up to further scrutiny, shows the benefit of the strategy of Horby and Martin Landray, the Oxford researchers who designed the study, leveraging the United Kingdom health system to start a study of multiple affordable potential Covid-19 therapies - including hydroxychloroquine, dexamethasone, and also some older HIV medicines.

England's chief medical officer, Chris Whitty, said Tuesday's announcement was "the most important trial result for COVID-19 so far", adding: "It will save lives around the world". This overreaction can prove fatal, so doctors have been testing steroids and other anti-inflammatory drugs in such patients.

Neither of those results, however, have been scrutinized or published.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE